{"id":40126,"date":"2025-11-07T09:48:35","date_gmt":"2025-11-07T04:48:35","guid":{"rendered":"https:\/\/menamedicalresearch.com\/news\/?p=40126"},"modified":"2025-11-07T09:51:52","modified_gmt":"2025-11-07T04:51:52","slug":"advancing-car-t-cell-therapy-in-solid-tumours","status":"publish","type":"post","link":"https:\/\/menamedicalresearch.com\/news\/cancers\/advancing-car-t-cell-therapy-in-solid-tumours\/","title":{"rendered":"Advancing CAR T-Cell Therapy in Solid Tumours"},"content":{"rendered":"<p>Chimeric Antigen Receptor (<strong>CAR) T-cell therapy has achieved transformative success in treating blood cancers,<\/strong> with certain B-cell malignancies showing complete remission rates exceeding 80%. However, <strong>applying this potent immunotherapy to solid tumors remains a formidable challenge<\/strong>.<\/p>\n<p>The <strong>primary hurdles stem from the hostile tumor microenvironment (TME)<\/strong>, which features heterogeneous antigen expression, physical barriers to T-cell infiltration, and an immunosuppressive nature that causes T-cell exhaustion. To overcome these obstacles, <strong>research is focused on continually refining the CAR T-cell design itself.<\/strong><\/p>\n<p>The field has advanced significantly <strong>through five successive generations of CAR design<\/strong>.<\/p>\n<ul>\n<li><strong>First-Generation CARs<\/strong> established the concept, but lacked the necessary co-stimulatory signals for sustained T-cell activation and persistence.<\/li>\n<li><strong>Second-generation CARs<\/strong> incorporated a single co-stimulatory domain (such as CD28 or 4-1BB), significantly improving T-cell proliferation and long-term durability.<\/li>\n<li><strong>Third-generation CARs<\/strong> combined multiple co-stimulatory domains to further amplify activation and ensure <strong>robust activation, proliferation, and durability<\/strong> following antigen engagement.<\/li>\n<li><strong>Fourth-Generation CARs<\/strong> (also known as &#8220;TRUCKS&#8221;), are engineered with an &#8220;armored&#8221; feature that allows them to secrete transgenic cytokines (like IL-12 or IL-18) directly at the tumor site. This payload is vital for enhancing T-cell activation and overcoming the immunosuppressive TME.<\/li>\n<li><strong>Fifth-Generation CARs<\/strong> further incorporate sophisticated elements like dual-targeting and synthetic Notch (synNotch) receptors. This ensures CAR T-cells are only triggered when two distinct tumor markers are present, improving specificity and minimizing off-tumor toxicity<\/li>\n<\/ul>\n<p><strong>The personalized process for manufacturing autologous CAR T-cells (using a patient&#8217;s own cells) is lengthy and costly<\/strong>. Therefore, the <strong>development of allogeneic or &#8220;off-the-shelf&#8221; CAR T-cells from healthy donors is a major priority, promising superior scalability and immediate availability<\/strong>. Modern tools like CRISPR-Cas9 gene editing are critical in creating these universal cells by enabling precise genetic modifications to knock out endogenous T-cell receptors and other immunogenic markers, reducing the risk of immune rejection.<\/p>\n<p>Despite the challenges, <strong>the potential of engineered T-cell therapy in solid tumors is now transitioning from experimental to clinical reality<\/strong>. 2024 saw the accelerated FDA approval approval of two different genetically modified T-cell therapies for solid cancers. The T-cell receptor (TCR) therapy afamitresgene autoleucel (afami-cel) was approved for advanced synovial sarcoma. Concurrently, the Tumor-Infiltrating Lymphocyte (TIL) therapy lifileucel was approved for unresectable or metastatic melanoma. These <strong>FDA approvals validate the potential for T-cell-based immunotherapies in solid tumors.<\/strong><\/p>\n<p>Future directions focus on regional delivery, combination treatments with checkpoint inhibitors, and the use of artificial intelligence (AI) for optimizing target discovery and trial design. <strong>With ongoing technological innovation, CAR T-cell therapy is poised to fundamentally reshape the future landscape of cancer immunotherapy for a wider patient population.<\/strong><\/p>\n<p><strong>Reference Source:<br \/>\n<\/strong>Rafii, S.; Mukherji, D.; Komaranchath, A.S.; Khalil, C.; Iqbal, F.; Abdelwahab, S.I.; Abyad, A.; Abuhelwa, A.Y.; Gandikota, L.; Al-Shamsi, H.O. Advancing CAR T-Cell Therapy in Solid Tumors: Current Landscape and Future Directions. <em>Cancers<\/em> 2025, <em>17<\/em>, 2898. DOI https:\/\/doi.org\/10.3390\/cancers17172898<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chimeric Antigen Receptor (CAR) T-cell therapy has achieved transformative success in treating blood cancers, with certain B-cell malignancies showing complete remission rates exceeding 80%. However, applying this potent immunotherapy to solid tumors remains a formidable challenge. The primary hurdles stem from the hostile tumor microenvironment (TME), which features heterogeneous antigen expression, physical barriers to T-cell &hellip;<\/p>\n","protected":false},"author":1,"featured_media":40129,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[39],"tags":[],"class_list":["post-40126","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancers"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO Pro 4.9.8 - aioseo.com -->\n\t<meta name=\"description\" content=\"Chimeric Antigen Receptor (CAR) T-cell therapy has achieved transformative success in treating blood cancers, with certain B-cell malignancies showing complete remission rates exceeding 80%. However, applying this potent immunotherapy to solid tumors remains a formidable challenge. The primary hurdles stem from the hostile tumor microenvironment (TME), which features heterogeneous antigen expression, physical barriers to T-cell\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"MENA Medical Research\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/menamedicalresearch.com\/news\/cancers\/advancing-car-t-cell-therapy-in-solid-tumours\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO Pro (AIOSEO) 4.9.8\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Mena Medical Research | Medical Research News from Middle East &amp; North Africa\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Advancing CAR T-Cell Therapy in Solid Tumours | Mena Medical Research\" \/>\n\t\t<meta property=\"og:description\" content=\"Chimeric Antigen Receptor (CAR) T-cell therapy has achieved transformative success in treating blood cancers, with certain B-cell malignancies showing complete remission rates exceeding 80%. However, applying this potent immunotherapy to solid tumors remains a formidable challenge. The primary hurdles stem from the hostile tumor microenvironment (TME), which features heterogeneous antigen expression, physical barriers to T-cell\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/menamedicalresearch.com\/news\/cancers\/advancing-car-t-cell-therapy-in-solid-tumours\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2025-11-07T04:48:35+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2025-11-07T04:51:52+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Advancing CAR T-Cell Therapy in Solid Tumours | Mena Medical Research\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Chimeric Antigen Receptor (CAR) T-cell therapy has achieved transformative success in treating blood cancers, with certain B-cell malignancies showing complete remission rates exceeding 80%. However, applying this potent immunotherapy to solid tumors remains a formidable challenge. The primary hurdles stem from the hostile tumor microenvironment (TME), which features heterogeneous antigen expression, physical barriers to T-cell\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/cancers\\\/advancing-car-t-cell-therapy-in-solid-tumours\\\/#article\",\"name\":\"Advancing CAR T-Cell Therapy in Solid Tumours | Mena Medical Research\",\"headline\":\"Advancing CAR T-Cell Therapy in Solid Tumours\",\"author\":{\"@id\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/author\\\/admin\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Car-T-Cell-Therapy-s-1.jpg\",\"width\":717,\"height\":490,\"caption\":\"Car-T cell therapy\"},\"datePublished\":\"2025-11-07T09:48:35+05:00\",\"dateModified\":\"2025-11-07T09:51:52+05:00\",\"inLanguage\":\"en-US\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/cancers\\\/advancing-car-t-cell-therapy-in-solid-tumours\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/cancers\\\/advancing-car-t-cell-therapy-in-solid-tumours\\\/#webpage\"},\"articleSection\":\"Cancers\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/cancers\\\/advancing-car-t-cell-therapy-in-solid-tumours\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/menamedicalresearch.com\\\/news#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/category\\\/cancers\\\/#listItem\",\"name\":\"Cancers\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/category\\\/cancers\\\/#listItem\",\"position\":2,\"name\":\"Cancers\",\"item\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/category\\\/cancers\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/cancers\\\/advancing-car-t-cell-therapy-in-solid-tumours\\\/#listItem\",\"name\":\"Advancing CAR T-Cell Therapy in Solid Tumours\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/menamedicalresearch.com\\\/news#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/cancers\\\/advancing-car-t-cell-therapy-in-solid-tumours\\\/#listItem\",\"position\":3,\"name\":\"Advancing CAR T-Cell Therapy in Solid Tumours\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/category\\\/cancers\\\/#listItem\",\"name\":\"Cancers\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/#organization\",\"name\":\"Mena Medical Research\",\"description\":\"Mena Medical Research Medical Research News from Middle East & North Africa\",\"url\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Mena-medical-research-favicon.png\",\"@id\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/cancers\\\/advancing-car-t-cell-therapy-in-solid-tumours\\\/#organizationLogo\",\"width\":118,\"height\":49},\"image\":{\"@id\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/cancers\\\/advancing-car-t-cell-therapy-in-solid-tumours\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/author\\\/admin\\\/#author\",\"url\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/author\\\/admin\\\/\",\"name\":\"MENA Medical Research\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/cancers\\\/advancing-car-t-cell-therapy-in-solid-tumours\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/510579871b05fb80e4c2259f81abd1814391f3afcb26ec9b6153d8fddb7810c3?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"MENA Medical Research\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/cancers\\\/advancing-car-t-cell-therapy-in-solid-tumours\\\/#webpage\",\"url\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/cancers\\\/advancing-car-t-cell-therapy-in-solid-tumours\\\/\",\"name\":\"Advancing CAR T-Cell Therapy in Solid Tumours | Mena Medical Research\",\"description\":\"Chimeric Antigen Receptor (CAR) T-cell therapy has achieved transformative success in treating blood cancers, with certain B-cell malignancies showing complete remission rates exceeding 80%. However, applying this potent immunotherapy to solid tumors remains a formidable challenge. The primary hurdles stem from the hostile tumor microenvironment (TME), which features heterogeneous antigen expression, physical barriers to T-cell\",\"inLanguage\":\"en-US\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/cancers\\\/advancing-car-t-cell-therapy-in-solid-tumours\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/author\\\/admin\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/author\\\/admin\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Car-T-Cell-Therapy-s-1.jpg\",\"@id\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/cancers\\\/advancing-car-t-cell-therapy-in-solid-tumours\\\/#mainImage\",\"width\":717,\"height\":490,\"caption\":\"Car-T cell therapy\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/cancers\\\/advancing-car-t-cell-therapy-in-solid-tumours\\\/#mainImage\"},\"datePublished\":\"2025-11-07T09:48:35+05:00\",\"dateModified\":\"2025-11-07T09:51:52+05:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/#website\",\"url\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/\",\"name\":\"Mena Medical Research\",\"description\":\"Medical Research News from Middle East & North Africa\",\"inLanguage\":\"en-US\",\"publisher\":{\"@id\":\"https:\\\/\\\/menamedicalresearch.com\\\/news\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO Pro -->\r\n\t\t<title>Advancing CAR T-Cell Therapy in Solid Tumours | Mena Medical Research<\/title>\n\n","aioseo_head_json":{"title":"Advancing CAR T-Cell Therapy in Solid Tumours | Mena Medical Research","description":"Chimeric Antigen Receptor (CAR) T-cell therapy has achieved transformative success in treating blood cancers, with certain B-cell malignancies showing complete remission rates exceeding 80%. However, applying this potent immunotherapy to solid tumors remains a formidable challenge. The primary hurdles stem from the hostile tumor microenvironment (TME), which features heterogeneous antigen expression, physical barriers to T-cell","canonical_url":"https:\/\/menamedicalresearch.com\/news\/cancers\/advancing-car-t-cell-therapy-in-solid-tumours\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/menamedicalresearch.com\/news\/cancers\/advancing-car-t-cell-therapy-in-solid-tumours\/#article","name":"Advancing CAR T-Cell Therapy in Solid Tumours | Mena Medical Research","headline":"Advancing CAR T-Cell Therapy in Solid Tumours","author":{"@id":"https:\/\/menamedicalresearch.com\/news\/author\/admin\/#author"},"publisher":{"@id":"https:\/\/menamedicalresearch.com\/news\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/menamedicalresearch.com\/news\/wp-content\/uploads\/2025\/11\/Car-T-Cell-Therapy-s-1.jpg","width":717,"height":490,"caption":"Car-T cell therapy"},"datePublished":"2025-11-07T09:48:35+05:00","dateModified":"2025-11-07T09:51:52+05:00","inLanguage":"en-US","mainEntityOfPage":{"@id":"https:\/\/menamedicalresearch.com\/news\/cancers\/advancing-car-t-cell-therapy-in-solid-tumours\/#webpage"},"isPartOf":{"@id":"https:\/\/menamedicalresearch.com\/news\/cancers\/advancing-car-t-cell-therapy-in-solid-tumours\/#webpage"},"articleSection":"Cancers"},{"@type":"BreadcrumbList","@id":"https:\/\/menamedicalresearch.com\/news\/cancers\/advancing-car-t-cell-therapy-in-solid-tumours\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/menamedicalresearch.com\/news#listItem","position":1,"name":"Home","item":"https:\/\/menamedicalresearch.com\/news","nextItem":{"@type":"ListItem","@id":"https:\/\/menamedicalresearch.com\/news\/category\/cancers\/#listItem","name":"Cancers"}},{"@type":"ListItem","@id":"https:\/\/menamedicalresearch.com\/news\/category\/cancers\/#listItem","position":2,"name":"Cancers","item":"https:\/\/menamedicalresearch.com\/news\/category\/cancers\/","nextItem":{"@type":"ListItem","@id":"https:\/\/menamedicalresearch.com\/news\/cancers\/advancing-car-t-cell-therapy-in-solid-tumours\/#listItem","name":"Advancing CAR T-Cell Therapy in Solid Tumours"},"previousItem":{"@type":"ListItem","@id":"https:\/\/menamedicalresearch.com\/news#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/menamedicalresearch.com\/news\/cancers\/advancing-car-t-cell-therapy-in-solid-tumours\/#listItem","position":3,"name":"Advancing CAR T-Cell Therapy in Solid Tumours","previousItem":{"@type":"ListItem","@id":"https:\/\/menamedicalresearch.com\/news\/category\/cancers\/#listItem","name":"Cancers"}}]},{"@type":"Organization","@id":"https:\/\/menamedicalresearch.com\/news\/#organization","name":"Mena Medical Research","description":"Mena Medical Research Medical Research News from Middle East & North Africa","url":"https:\/\/menamedicalresearch.com\/news\/","logo":{"@type":"ImageObject","url":"https:\/\/menamedicalresearch.com\/news\/wp-content\/uploads\/2025\/11\/Mena-medical-research-favicon.png","@id":"https:\/\/menamedicalresearch.com\/news\/cancers\/advancing-car-t-cell-therapy-in-solid-tumours\/#organizationLogo","width":118,"height":49},"image":{"@id":"https:\/\/menamedicalresearch.com\/news\/cancers\/advancing-car-t-cell-therapy-in-solid-tumours\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/menamedicalresearch.com\/news\/author\/admin\/#author","url":"https:\/\/menamedicalresearch.com\/news\/author\/admin\/","name":"MENA Medical Research","image":{"@type":"ImageObject","@id":"https:\/\/menamedicalresearch.com\/news\/cancers\/advancing-car-t-cell-therapy-in-solid-tumours\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/510579871b05fb80e4c2259f81abd1814391f3afcb26ec9b6153d8fddb7810c3?s=96&d=mm&r=g","width":96,"height":96,"caption":"MENA Medical Research"}},{"@type":"WebPage","@id":"https:\/\/menamedicalresearch.com\/news\/cancers\/advancing-car-t-cell-therapy-in-solid-tumours\/#webpage","url":"https:\/\/menamedicalresearch.com\/news\/cancers\/advancing-car-t-cell-therapy-in-solid-tumours\/","name":"Advancing CAR T-Cell Therapy in Solid Tumours | Mena Medical Research","description":"Chimeric Antigen Receptor (CAR) T-cell therapy has achieved transformative success in treating blood cancers, with certain B-cell malignancies showing complete remission rates exceeding 80%. However, applying this potent immunotherapy to solid tumors remains a formidable challenge. The primary hurdles stem from the hostile tumor microenvironment (TME), which features heterogeneous antigen expression, physical barriers to T-cell","inLanguage":"en-US","isPartOf":{"@id":"https:\/\/menamedicalresearch.com\/news\/#website"},"breadcrumb":{"@id":"https:\/\/menamedicalresearch.com\/news\/cancers\/advancing-car-t-cell-therapy-in-solid-tumours\/#breadcrumblist"},"author":{"@id":"https:\/\/menamedicalresearch.com\/news\/author\/admin\/#author"},"creator":{"@id":"https:\/\/menamedicalresearch.com\/news\/author\/admin\/#author"},"image":{"@type":"ImageObject","url":"https:\/\/menamedicalresearch.com\/news\/wp-content\/uploads\/2025\/11\/Car-T-Cell-Therapy-s-1.jpg","@id":"https:\/\/menamedicalresearch.com\/news\/cancers\/advancing-car-t-cell-therapy-in-solid-tumours\/#mainImage","width":717,"height":490,"caption":"Car-T cell therapy"},"primaryImageOfPage":{"@id":"https:\/\/menamedicalresearch.com\/news\/cancers\/advancing-car-t-cell-therapy-in-solid-tumours\/#mainImage"},"datePublished":"2025-11-07T09:48:35+05:00","dateModified":"2025-11-07T09:51:52+05:00"},{"@type":"WebSite","@id":"https:\/\/menamedicalresearch.com\/news\/#website","url":"https:\/\/menamedicalresearch.com\/news\/","name":"Mena Medical Research","description":"Medical Research News from Middle East & North Africa","inLanguage":"en-US","publisher":{"@id":"https:\/\/menamedicalresearch.com\/news\/#organization"}}]},"og:locale":"en_US","og:site_name":"Mena Medical Research | Medical Research News from Middle East &amp; North Africa","og:type":"article","og:title":"Advancing CAR T-Cell Therapy in Solid Tumours | Mena Medical Research","og:description":"Chimeric Antigen Receptor (CAR) T-cell therapy has achieved transformative success in treating blood cancers, with certain B-cell malignancies showing complete remission rates exceeding 80%. However, applying this potent immunotherapy to solid tumors remains a formidable challenge. The primary hurdles stem from the hostile tumor microenvironment (TME), which features heterogeneous antigen expression, physical barriers to T-cell","og:url":"https:\/\/menamedicalresearch.com\/news\/cancers\/advancing-car-t-cell-therapy-in-solid-tumours\/","article:published_time":"2025-11-07T04:48:35+00:00","article:modified_time":"2025-11-07T04:51:52+00:00","twitter:card":"summary","twitter:title":"Advancing CAR T-Cell Therapy in Solid Tumours | Mena Medical Research","twitter:description":"Chimeric Antigen Receptor (CAR) T-cell therapy has achieved transformative success in treating blood cancers, with certain B-cell malignancies showing complete remission rates exceeding 80%. However, applying this potent immunotherapy to solid tumors remains a formidable challenge. The primary hurdles stem from the hostile tumor microenvironment (TME), which features heterogeneous antigen expression, physical barriers to T-cell"},"aioseo_meta_data":{"post_id":"40126","title":null,"description":null,"keywords":null,"keyphrases":{"focus":{"keyphrase":"CAR T-Cell Therapy in Solid Tumours","score":0,"analysis":[]}},"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"Article","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"seo_analyzer_scan_date":"2026-06-02 07:51:03","breadcrumb_settings":null,"limit_modified_date":false,"open_ai":null,"ai":{"faqs":[],"keyPoints":[],"titles":[],"descriptions":[],"socialPosts":{"email":[],"linkedin":[],"twitter":[],"facebook":[],"instagram":[]}},"created":"2025-11-07 04:39:06","updated":"2026-06-02 07:51:03"},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t<a href=\"https:\/\/menamedicalresearch.com\/news\" title=\"Home\">Home<\/a>\n<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t<a href=\"https:\/\/menamedicalresearch.com\/news\/category\/cancers\/\" title=\"Cancers\">Cancers<\/a>\n<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\tAdvancing CAR T-Cell Therapy in Solid Tumours\n<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/menamedicalresearch.com\/news"},{"label":"Cancers","link":"https:\/\/menamedicalresearch.com\/news\/category\/cancers\/"},{"label":"Advancing CAR T-Cell Therapy in Solid Tumours","link":"https:\/\/menamedicalresearch.com\/news\/cancers\/advancing-car-t-cell-therapy-in-solid-tumours\/"}],"_links":{"self":[{"href":"https:\/\/menamedicalresearch.com\/news\/wp-json\/wp\/v2\/posts\/40126","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/menamedicalresearch.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/menamedicalresearch.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/menamedicalresearch.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/menamedicalresearch.com\/news\/wp-json\/wp\/v2\/comments?post=40126"}],"version-history":[{"count":1,"href":"https:\/\/menamedicalresearch.com\/news\/wp-json\/wp\/v2\/posts\/40126\/revisions"}],"predecessor-version":[{"id":40128,"href":"https:\/\/menamedicalresearch.com\/news\/wp-json\/wp\/v2\/posts\/40126\/revisions\/40128"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/menamedicalresearch.com\/news\/wp-json\/wp\/v2\/media\/40129"}],"wp:attachment":[{"href":"https:\/\/menamedicalresearch.com\/news\/wp-json\/wp\/v2\/media?parent=40126"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/menamedicalresearch.com\/news\/wp-json\/wp\/v2\/categories?post=40126"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/menamedicalresearch.com\/news\/wp-json\/wp\/v2\/tags?post=40126"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}